Treatment of p53-Deficient Cancers by Adenovirus E1B-Region Mutants
作者： David H. Kirn
DOI: 10.1007/978-1-59259-218-0_30
关键词: Mutant 、 Dose escalation 、 Radiation therapy 、 Medicine 、 Toxicity 、 Tumor growth inhibition 、 Cancer research 、 Normal tissue 、 Cancer cell 、 Chemotherapy
摘要: The vast majority of human cancers are incurable once they have become metastatic. Chemotherapy and radiotherapy can induce tumor growth inhibition or regression in some cases, but solid progression resistance to these standard therapeutic modalities inevitably develop. Further dose escalation overcome is generally limited by the resultant toxicity normal tissues. Clearly, new agents with larger indices between cancer cells needed. Such would improved efficacy reduced as compared currently available modalities.
springer.com
sci-hub.st 参考文章(18)
L S Young, A G Eliopoulos, S Krajewski, J C Reed, D J Kerr, J Herod, L Hodgkins, The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. ,vol. 11, pp. 1217- 1228 ,(1995)
G A Prince, H S Ginsberg, The molecular basis of adenovirus pathogenesis. Infectious agents and disease. ,vol. 3, pp. 1- 8 ,(1994)
Brian E. Huber, Vincent C. Knick, Doris M. Murray, Elizabeth A. Austin, Quynh T. Trinh, Enzyme/Prodrug Gene Therapy: Comparison of Cytosine Deaminase/5-Fluorocytosine Versus Thymidine Kinase/Ganciclovir Enzyme/Prodrug Systems in a Human Colorectal Carcinoma Cell Line Cancer Research. ,vol. 55, pp. 4808- 4812 ,(1995)
Jhingook Kim, Helmuth Goepfert, Jae Y. Ro, Jack A. Roth, Waun K. Hong, Tapas Mukhopadhyay, Kyung Y. Chung, Alan Casson, Discordant p53 Gene Mutations in Primary Head and Neck Cancers and Corresponding Second Primary Cancers of the Upper Aerodigestive Tract Cancer Research. ,vol. 53, pp. 1676- 1683 ,(1993)
Bert Vogelstein, David Sidransky, Ruth W. Craig, Michael B. Kastan, Onyinye Onyekwere, Participation of p53 Protein in the Cellular Response to DNA Damage Cancer Research. ,vol. 51, pp. 6304- 6311 ,(1991)
T. Dobner, N. Horikoshi, S. Rubenwolf, T. Shenk, Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor Science. ,vol. 272, pp. 1470- 1473 ,(1996) , 10.1126/SCIENCE.272.5267.1470
Carla Heise, Adam Sampson-Johannes, Angelica Williams, Frank Mccormick, Daniel D. Von Hoff, David H. Kirn, ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine. ,vol. 3, pp. 639- 645 ,(1997) , 10.1038/NM0697-639
Douglas D. Barker, Arnold J. Berk, Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology. ,vol. 156, pp. 107- 121 ,(1987) , 10.1016/0042-6822(87)90441-7
J. R. Bischoff, D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, F. McCormick, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. ,vol. 274, pp. 373- 376 ,(1996) , 10.1126/SCIENCE.274.5286.373
Martin Scheffner, Bruce A. Werness, Jon M. Huibregtse, Arnold J. Levine, Peter M. Howley, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 Cell. ,vol. 63, pp. 1129- 1136 ,(1990) , 10.1016/0092-8674(90)90409-8